Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Hong Kong · Delayed Price · Currency is HKD

483.80

+2.80 (0.58%)

Jul 31, 2026, 4:08 PM HKT

HKG:6990 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2,058	2,058	1,933	1,540	803.93	32.32
Revenue Growth	37.13%	6.46%	25.48%	91.62%	2387.26%	-
Gross Profit	1,479	1,479	1,274	759.19	526.8	9.25
Operating Income	-419.57	-419.57	-279.22	-453.7	-393.95	-795.24
Net Income	-381.97	-381.97	-266.77	-522.21	-548.1	-822.55
Earnings Per Share	-1.66	-1.66	-1.20	-2.84	-5.74	-8.90
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
The PRC	571.2	571.2	92.65	7.54	56.49	20.39
The United States of America	1,315	1,315	1,840	1,528	730.04	-
Switzerland	168.69	168.69	-	-	-	-
Other Countries	3.31	3.31	-	4.73	17.41	11.94
Total	2,058	2,058	1,933	1,540	803.93	32.32

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	4,472	4,472	3,069	2,488	92.96	81.79
Total Debt	88.44	88.44	126.75	59.92	3,014	2,391
Net Cash (Debt)	4,383	4,383	2,942	2,428	-2,921	-2,309
Net Cash Growth	0.00%	48.99%	21.15%	-	-	-
Net Cash Per Share	19.01	19.01	13.27	13.22	-30.58	-24.98

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-180.3	-180.3	-429.77	59.56	-270.85	-485.94
Capital Expenditures	-125.69	-125.69	-77.46	-80.98	-33.66	-94.08
Free Cash Flow	-305.99	-305.99	-507.23	-21.42	-304.51	-580.03
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	71.86%	71.86%	65.89%	49.28%	65.53%	28.62%
Operating Margin	-20.39%	-20.39%	-14.45%	-29.45%	-49.00%	-2460.37%
Pretax Margin	-17.29%	-17.29%	-7.37%	-30.36%	-70.57%	-2752.91%
Profit Margin	-18.56%	-18.56%	-13.80%	-33.90%	-68.18%	-2544.86%
FCF Margin	-14.87%	-14.87%	-26.24%	-1.39%	-37.88%	-1794.52%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 1, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PS Ratio	50.50	39.94	18.04	13.29	-	-